Investors
We are an early commercial stage medtech company working to bring fully automated molecular tests to dermatology at the point of need. Dermagnostix’ product pipeline includes molecular tests for disease diagnosis, inflammatory biomarker pattern identification and prediction of treatment response.
Skin health matters for human well-being
incidences of psoriasis², atopic dermatitis³ have doubled during the past decades. Often chronic, un-curable and disfiguring, skin diseases impair patients’ quality of life more drastically than cancer and diabetes⁴
’
Novel biologics and small-molecule inhibitors have revolutionized treatment options and significantly fueled dermatology drug size market which – already in 2021 - was valued at more than 26 billion US dollar⁶. Yet, diagnostics have not kept pace with therapeutic advances creating a huge gap between diagnostics and therapeutics. To fully leverage the potential of modern drugs, objective, molecular diagnostics is urgently needed to complement conventional diagnostics.
Dermagnostix offers molecular diagnostic solutions to close the gap and meet the need for personalized care.
From Science to product – Dermagnostix offers comprehensive molecular diagnostic solutions
Dermagnostix provides unique diagnostic tests for unmet clinical needs in dermatology on a fully automated portable laboratory. With PsorX (CE-IVD), Dermagnostix launches the first in-class molecular test for differential diagnosis of psoriasis and eczema.
Upcoming events
Awards
2023
2022
2022
2021
2020
2020
2020
2020
2020
2020
2019
2018
Certification
Since November 2022 Dermagnostix is officially EN ISO 13485 certified
view certificate
Latest news
DX featured at Kompass Dermatologie
Dermagnostix is featured in the journal series ‘Karger Kompass’ aimed at clinicians and specialists in private practice with a focus on young, committed physicians with four specialist target groups of pneumologists, dermatologists, oncologists and ophthalmologists.
References
- Flohr C, Hay R. Putting the burden of skin diseases on the global map. The British journal of dermatology 2021;184:189-90
- Andersen LK, Davis MD. The epidemiology of skin and skin-related diseases: a review of population-based studies performed by using the Rochester Epidemiology Project. Mayo Clinic proceedings 2013;88:1462-7.
- Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab 2015;66 Suppl 1:8-16
- Montero-Vílchez T, Sánchez-Díaz M, Martínez-López A, et al. (2022): Quality of Life in Patients with Skin Disease and Their Cohabitants. Health-Related Quality of Life - Measurement Tools, Predictors and Modifiers. IntechOpen. DOI: 10.5772/intechopen.97450.
- Neurodermitisreport (tk.de)
- Dermatology Drug Market 2023 Size with Business Forecast up to 2027 & In-Depth Analysis in LATEST REPORT - MarketWatch
Want to know more?
Natalie Garzorz-Stark, MD, PhD, MHBA
Co-Founder & CEO
info@dermagnostix.com